Cargando…
Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis
Autores principales: | Haddox, C L, Mangaonkar, A A, Chen, D, Shi, M, He, R, Oliveira, J L, Litzow, M R, Al-Kali, A, Hogan, W J, Elliott, M A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637108/ https://www.ncbi.nlm.nih.gov/pubmed/29016570 http://dx.doi.org/10.1038/bcj.2017.89 |
Ejemplares similares
-
Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia
por: He, Rui R., et al.
Publicado: (2019) -
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy
por: Coorens, Tim H. H., et al.
Publicado: (2023) -
Aggressive Clinicopathological Course of Myeloma with t(3;16) (q21;q22) Cytogenetic Abnormality
por: Bozkurt, Süreyya, et al.
Publicado: (2019) -
PAX5 alterations in an infant case of KMT2A‐rearranged leukemia with lineage switch
por: Nakajima, Koji, et al.
Publicado: (2022) -
qPCR as a Selective Tool for Cytogenetics
por: Divashuk, Mikhail G., et al.
Publicado: (2022)